Crossject

Crossject Days Payable Outstanding

The Days Payable Outstanding (DPO) of Crossject (ALCJ.PA) as of Oct 28, 2026 is 71.76. In the previous year, Days Payable Outstanding (DPO) was 342.94 — a change of -79.07% (lower).

Days Payable Outstanding

71.76

YoY

-79.07%

Last updated:

Days Payable Outstanding (DPO) of Crossject is 2025 71.76 . Days Payable Outstanding (DPO) of Crossject was 2024 342.94 . It decreases by -79.07% lower compared to the previous year.

The Crossject Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
315.83 EUR
Jan 1, 2019
67.20 EUR
Jan 1, 2020
217.65 EUR
Jan 1, 2021
59.77 EUR
Jan 1, 2022
86.55 EUR
Jan 1, 2023
85.32 EUR
Jan 1, 2024
342.94 EUR
Jan 1, 2025
71.76 EUR
The Crossject Days Payable Outstanding history
YEARDays Payable OutstandingYoY
71.76-79.07%
342.94+301.94%
85.32-1.43%
86.55+44.81%
59.77-72.54%
217.65+223.90%
67.20-78.72%
315.83-25.63%
424.66+71.43%
247.72-45.66%
455.82+244.74%
132.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Crossject Stock analysis

What does Crossject do? Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Crossject stock

Days Payable Outstanding (DPO) of Crossject is 71.76 in 2025.

Days Payable Outstanding (DPO) of Crossject changed from 342.94 to 71.76, representing a -79.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Crossject since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Crossject with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Crossject

All Key Metrics — Crossject